Early human evidence
A randomized first-in-human paper reports tolerability and pharmacokinetics, with weekly exposure studied over 12 weeks.
Explore the published study →UBT251.
UBT251 targets GLP-1, GIP and glucagon receptors in one investigational molecule. Researchers study its effects on body weight and glucose regulation, while community interest includes how its receptor balance might compare with Retatrutide.
Research focus: Weight reduction and glucose regulation.
Choose a compound to open its research, documentation and calculator.
QUICK REFERENCE
Checked October 15, 2026The essentials.
- FDA statusFDA status and scope
No FDA-approved drug product for this catalog material. Compounding eligibility and approval are separate questions.
Official source ↗ - Not FDA approved
- Half-lifeHalf-life: source and route
The reviewed material does not establish a half-life for this exact material and route.
Half-life describes concentration falling by half. It does not set a dosing interval, a storage period or a drug-test detection window.
Kinetics source ↗ - Not established hereNo verified value
- Diluent / formulationDiluent and formulation
No validated common diluent for this exact material was established by the sources reviewed here. Component recipes do not establish blend compatibility.
Bacteriostatic water contains a preservative; plain sterile water does not. Preservative presence does not by itself establish compatibility or a mixed medicine’s usable period.
Preparation source ↗ - Check the exact formulationNo universal recipe
What the documentation tells us.
Evidence context
UBT251 is investigational. Shared receptors do not establish equivalent doses, safety or outcomes with Retatrutide. Trial preparations and schedules do not identify a separately supplied product.
Check that a source concerns the same molecule, formulation, route and population. A study of cells, animals or a different product cannot confirm the contents of a vial.
Early human paper, phase 2 conference abstract, sponsor reports and a separate community comparison.
Another approach to triple agonism.
A single molecule is designed to activate GLP-1, GIP and glucagon receptors. That puts UBT251 in the same broad research class as Retatrutide. Each molecule’s receptor activity, exposure and clinical outcomes still need to be measured separately.
19.7% at 24 weeks
The highest reported mean weight loss came from a specific 4 mg target arm, starting at 1 mg, in 205 Chinese adults. Placebo was 2.0%.
Keep the trial context beside the result →The receptor-balance question: a community post proposes a smaller glucagon contribution than Retatrutide. The reviewed primary reports do not establish that ranking, a superior safety profile or a dose conversion.
UBT251: the evidence so farResults, receptor balance and what comes next →Explore RetatrutideThe related molecule’s separate evidence →
Other names you may encounter: UBT-251.
Learn to read a study →Community schedules and research routes.
Dosage & schedule options.
Reading these schedules
Each entry keeps one schedule’s amount, frequency and cycle together. Community references, individual reports, clinical trials and prescription products describe different kinds of use. A missing duration or break stays marked as not reported.
Amounts describe mass in mg or mcg. Syringe units describe volume and depend on concentration. A cycle break is different from days off within a week.
Choose an option to explore its amounts, timing and cycle.
Reported protocolWeekly injections · lower-start trial arm
- Dose
- 0.5 mg initial amount → 4 mg target
- How often
- Once weekly
- Route
- Subcutaneous
- Duration
- 24 weeks
- Break after cycle
- No repeating cycle or washout regimen supplied
The complete sequence of escalation steps was not reported. This is a clinical-trial arm.
Reported protocolWeekly injections · higher-start trial arm
- Dose
- 1 mg initial amount → 4 mg target
- How often
- Once weekly
- Route
- Subcutaneous
- Duration
- 24 weeks
- Break after cycle
- No repeating cycle or washout regimen supplied
A separate clinical-trial arm with a different starting amount and the same 4 mg target.
Community research & perspectives.
About community labels
Community identifies source origin. It does not certify independent funding, medical credentials or the strength of a claim. Source types distinguish published reports, professional explanations and public discussions.
Explore reports, explanations and discussions from medical practices, researchers, suppliers and community members. The badges identify the source’s origin and evidence type.
How to read these source labels →CommunityCommunity discussion
UBT251 and Retatrutide: a community comparison
UBT251 and Retatrutide: a community comparison: evidence & source context
A forum explainer is not a head-to-head trial or an independently measured UBT251 receptor-potency table. Cross-trial outcomes cannot prove superiority, and an unreported adverse-event signal is not evidence of absence.
Source relationship: The post recommends a named supplier and describes a product without an available lot-specific certificate at the time of writing. Any financial relationship is unverified. Inclusion is not a supplier or product endorsement.
The post compares triple-receptor targets, trial headlines and a proposed difference in glucagon weighting. Its receptor-balance and tolerability interpretations are discussed alongside primary sources in our UBT251 research article.
Community interpretation · includes supplier promotion · clinical credentials unverified
Reconstitution, storage and devices.
Product-specific handling
A peptide name and vial mass cannot determine a compatible diluent, powder displacement, storage temperature or discard date. Follow the exact product’s instructions and your pharmacist’s directions.
The injection guide concerns clinician-prescribed subcutaneous medicines; it does not establish that a research-labeled material can be injected.
Start with the formulation: dry powder, prepared solution, pen, tablet and topical product can have different instructions.
Storage: before and after opening.
UBT251 · dry and prepared material
- Before opening
- Temperature and expiry: use the exact lot’s documentation. Keep the original label with the vial.
- After mixing / first use
- No universal storage window is verified in this guide. Obtain the exact preparation’s temperature and discard date.
- Handling & discard
- Record the mixing or first-puncture date. The diluent’s discard date is separate from the mixed preparation’s date.
Trial publications concern their documented study preparations. The selected sources do not provide a universal diluent, mixing volume, refrigerated storage period or discard date for separately supplied UBT251 powder.
See the research we’re following ↓Habits & tracking that help.
General health habits and consistent observations help you assess changes. They are not evidence that a peptide’s effects will be amplified.
Include movement and strength work
Choose activity that fits your health and ability. Aerobic movement and muscle-strengthening work are part of general adult activity guidance.
CDC · adult activity ↗Keep a consistent sleep routine
Use a regular sleep/wake schedule and note changes in sleep quality alongside symptoms or training.
CDC · sleep habits ↗What to record: Track food intake, appetite, activity and tolerability together. Appetite control should still leave room for adequate meals; review persistent eating difficulties with the treating clinician.
Documentation behind UBT251.
About source checks
Check dates are editorial references, not a medical review certificate. Labels and evidence can change; consult the linked current document.
StudyUBT251: published phase 1a/1b safety and pharmacokineticsStudyADA 3090-LB: phase 2 obesity conference abstractSponsor updateNovo / TUL: Chinese obesity trial topline results, February 2026Sponsor updateNovo / TUL: type 2 diabetes trial topline results, March 2026Trial registryClinicalTrials.gov: Chinese phase 2 obesity trialTrial registryClinicalTrials.gov: global obesity programTrial registryClinicalTrials.gov: global type 2 diabetes dose-finding trial
Study details, timing & schedule comparisons
Study arms, with the starting-dose detail.
About UBT251 trial schedules
The arms below describe a controlled research study, not a personal starting or escalation plan. Identical mg values do not imply equivalent effects across UBT251 and Retatrutide. The abstract does not supply a complete universal titration schedule.
The Chinese phase 2 obesity study used once-weekly subcutaneous administration for 24 weeks. Two groups had a 4 mg target but different initial amounts.
| Target arm | Initial amount | Mean weight loss |
|---|---|---|
| 2 mg | Not specified here | 13.6% |
| 4 mg | 0.5 mg | 16.2% |
| 4 mg | 1 mg | 19.7% |
| 6 mg | Not specified here | 18.7% |
| Placebo | — | 2.0% |
The 4 mg / 1 mg-start arm’s numerical result does not prove that 4 mg is optimal or that a faster start is preferable. Group estimates, exposure duration and adverse events belong together.
Read the original conference abstract ↗STUDIES WORTH UNDERSTANDING
How to read a studyBeyond the headline.
Selected studies and clinical reports, with the question, context and limitations close at hand.
Phase 1a/1b2026
UBT251: the first-in-human phase 1a/1b study
What did early human testing show about tolerability and drug exposure?
- Participants
- First-in-human cohorts
- Follow-up
- Single exposure / 12 weeks
Conference abstract2026
UBT251: the 24-week phase 2 obesity results
Which trial arm produced the 19.7% weight-loss headline?
- Participants
- 205 Chinese adults
- Follow-up
- 24 weeks
What we’re following next.
About trial status and future updates
These are registry listings checked October 9, 2026, not live enrollment counts. Planned enrollment and estimated completion dates can change. We revise this guide as new reports and registry records are reviewed; a registered study is not a completed result.
The next questions include longer follow-up, broader populations, detailed safety findings and directly measured receptor activity. Those answers can refine the comparison with Retatrutide.
Global overweight / obesity study
Listed as recruiting · 333 planned
Broader population, exposure and tolerability; estimated primary completion in January 2027.
NCT07395687 ↗Global type 2 diabetes dose-finding
Listed as recruiting · 300 planned
Blood-glucose response and tolerability; estimated primary completion in October 2027.
NCT07668388 ↗China overweight / obesity program
Listed as not yet recruiting · 600 planned
Larger, longer confirmation of the phase 2 obesity findings.
NCT07648225 ↗China type 2 diabetes · UNIGUIDE-1
Listed as recruiting · 360 planned
Confirmatory glycemic outcomes in people managed with diet and exercise.
NCT07659574 ↗UBT251 calculator.
About calculator examples
Opening values and worked examples illustrate arithmetic; they are not preparation instructions or recommended amounts. Selecting a compound labels the calculation and does not supply a dose or powder-volume correction.
Enter the documented vial mass, preparation information and target amount to see how mass and volume connect.
An arithmetic example
20 mg in an assumed final 1 mL gives 20 mg/mL. An entered 1 mg corresponds to 0.05 mL, or 5 U-100 units, with 20 theoretical portions before losses.
YOUR CALCULATION WORKSPACE
Open focused view →Three tools. Clear numbers.
01 / YOUR INPUTS
Calculator inputsStarting numbers are worked examples, not recommended doses or preparation instructions. Dose-to-units and units-to-dose views describe the same quantities. The calculator defaults to 1 mL (100 U-100 units) of liquid added as an estimate of total solution volume.In plain EnglishChoose the amount on your vial label, the liquid you added, and the amount per dose you already want to calculate. Type an exact amount or use the slider; neither selects a dose for you.Vial → dose → syringe
CompoundSelect a name to organize your calculation. Names do not set the vial mass, target amount, or volume. NAD+ is a related compound, not a peptide. For blends, enter each component’s mass separately.In plain EnglishThis is the label on your calculation, like naming a folder. Choosing a name does not decide how much material or liquid to use.
Amount in the vialThe total mass of this compound in the vial, not its concentration. Use the mass stated in your source documentation. 1 mg = 1,000 mcg.In plain EnglishThink of mass as the amount of material you started with. Adding liquid spreads that material out; it does not create more of it. A vial marked 5 mg contains 5,000 mcg.
mg
Liquid added to the vialThe starting 1 mL (100 U-100 units) is an editable example. For a general estimate, we use the liquid added as the total solution volume; powder displacement is not included. If your preparation specifies a different final volume, enter it in Advanced. The calculator does not choose a diluent or mixing procedure.In plain English100 units on a U-100 syringe means 1 mL of liquid added; 200 units in total means 2 mL. The starting 1 mL (100 U-100 units) is an editable calculator example, not a mixing recommendation for every product. The simple calculation uses added liquid as an estimate of final volume. A correction needs data for the specific formulation, not just a peptide name. Enter a documented final volume in Advanced when available.
mL
Amount per doseType your exact amount, or adjust the 1–20 mg slider in whole-mg steps or click a labeled value. Type decimal amounts directly in the field. The slider range is a navigation shortcut, not a recommended dose range. Amounts below 1 mg or above 20 mg can be typed directly. Switching mg/mcg preserves the amount.In plain EnglishThe amount in the vial describes the whole batch. This input describes just one portion. For example, if a 5 mg vial makes 20 equal portions, each contains 0.25 mg (250 mcg). Enter the amount from your protocol and the calculator finds the liquid volume for it.
Advanced Volume & syringe settings
Calculation basisA stated concentration is product-specific and refers to the selected blend component. It does not reveal a recoverable fill volume or establish the product’s allowed number of doses. Entering a different compound or blend component clears this concentration.In plain EnglishUse the mg/mL printed on your product label when you have it. Otherwise, you can use a documented final volume or keep the liquid-added estimate.
Syringe capacityOn a U-100 scale, 100 markings equal 1 mL. Capacity changes the displayed scale, not the concentration. These markings are not compound activity units (IU).In plain EnglishCapacity is how much liquid the syringe can hold when full. On a U-100 syringe, 10 units means 0.1 mL, and 100 units means 1 mL. A smaller syringe holds less, but each U-100 unit still means 0.01 mL.
Marked intervalRead the actual graduation spacing on your device. This setting flags values that fall between markings; it does not round the calculation or guarantee measurement accuracy.In plain EnglishThese are the steps between lines on your syringe. Like a ruler, a value can land between two lines. The calculator points that out instead of moving the answer to a nearby line.
02 / YOUR RESULTCalculated
UBT251
Estimate · assumes 1 mL added = total volume
U-100 syringe1 mL capacity · 100 unitsSyringe capacityAll unit conversions here use a U-100 scale: 100 units = 1 mL. The selected capacity changes the maximum volume shown, not the concentration. These are volume scale units, not compound activity units (IU).In plain EnglishCapacity is how much liquid the syringe can hold when full. On a U-100 syringe, 10 units means 0.1 mL, and 100 units means 1 mL. A smaller syringe holds less, but each U-100 unit still means 0.01 mL.
- Amount per dose
- 1 mg
- Full doses per vial Doses per vialTotal vial mass divided by the entered dose amount, rounded down to complete doses. This is a theoretical count before handling losses. It may exceed the labeled usable doses because of overfill or discard instructions. A single-dose vial is not reusable just because arithmetic shows more portions.In plain EnglishAn aliquot is just a portion. This is how many full, equally sized portions the mixture could make in perfect conditions, like counting full glasses from a pitcher.
- 5
- Syringe amount per dose Result displayBoth views describe the same calculated volume. U-100 scale units = volume in mL × 100. Changing the display does not change the concentration, target amount, or calculation. This conversion does not apply to other syringe scales or biological activity units (IU).In plain EnglishThe liquid amount stays the same when you switch views. It is like showing the same distance in centimeters or inches: only the number and label change. Here, 0.1 mL is 10 units on a U-100 syringe.
- 20units
- Amount remaining Amount remainingThe selected compound’s vial mass minus the mass in complete doses. This is a theoretical remainder, not a measured or recoverable amount; overfill, dead space, transfer losses and product discard rules are excluded.In plain EnglishAfter counting all the full doses, this is the amount left over on paper. A result of 0 mg means the amounts divide evenly; handling losses can still leave you with fewer usable doses.
- 0 mg
1,000 mcg
Theoretical · before losses
0.2 mL
After 5 full doses
U-100 volume scaleVolume scaleThis illustration shows calculated volume against the selected capacity. It is not a physical measurement tool. The value is not rounded to the smallest marked interval.In plain EnglishThe picture helps you compare the answer with the syringe you selected. It is a drawing, so do not hold a real syringe up to your screen to measure liquid.
Illustration only · calculated value, without rounding
Concentration & remaining liquid
- Concentration ConcentrationMass divided by final solution volume. For a blend, this is the selected component’s concentration.In plain EnglishThink of juice concentrate: the same amount of concentrate in less water makes a stronger mixture. Here, mg/mL tells you how much material is in each 1 mL of liquid.
- 5 mg/mL
- Per U-100 unit Amount per scale unitOne U-100 scale unit represents 0.01 mL. This is the mass of the selected compound in that volume.In plain EnglishEach U-100 unit is a tiny portion of liquid: one hundredth of a milliliter. This number tells you how much material is inside that tiny portion.
- 50 mcg
- Full portions in vial Complete aliquotsTheoretical count of complete portions at the calculated volume. This excludes transfer loss, dead space, and any change in solution volume.In plain EnglishAn aliquot is just a portion. This is how many full, equally sized portions the mixture could make in perfect conditions, like counting full glasses from a pitcher.
- 5
- Theoretical remainder Remaining volumeMass-equivalent liquid remaining after complete portions. This is not a measured fill or recoverable volume. Handling losses, overfill and product discard rules are not included.In plain EnglishThis is a paper-and-pencil remainder: leftover compound mass expressed as liquid. It does not measure what can be recovered from the vial. Losses and product discard instructions can make the usable amount smaller.
- 0 mL
Saved calculations stay on this device.
See the calculation
Concentration = mass ÷ final volume
5 mg ÷ 1 mL = 5 mg/mLVolume = target mass ÷ concentration
1 mg ÷ 5 mg/mL = 0.2 mLU-100 markings = volume × 100
0.2 mL × 100 = 20 unitsComplete portions = floor(vial mass ÷ amount per portion).
Displayed numbers are rounded for readability; the calculation uses unrounded values.
CONCENTRATION → VOLUME
Dosage calculatorUse the documented concentration and an amount you already want to calculate. U-100 units are volume markings, not biological activity units or IU.Convert a known dose.
Already have the concentration? Find the matching mL and U-100 syringe reading.
Need the concentration first? Use the Reconstitution tab.
YOUR CONVERSION
On a U-100 syringe
5units
0.05 mL · 0.25 mg
Volume = target amount ÷ concentration
0.25 mg ÷ 5 mg/mL = 0.05 mLU-100 units = mL × 100Example inputs are editable. The reading is calculated without rounding to a physical graduation.
ONE MEASUREMENT, ANOTHER UNIT
Mass, volume and activity unitsMass and volume are separate dimensions. Converting between them requires a concentration. IU describes biological activity and has no universal conversion to mg or syringe units.Keep the units clear.
Convert mass or liquid volume. U-100 markings always refer to a 100-units-per-mL scale.
YOUR CONVERSION
1 mg equals
1,000mcg
1 g = 1,000 mg = 1,000,000 mcg
For mass → syringe volume, switch to Dosage and enter a concentration.